Osteoporosis is characterized by micro-architectural deterioration of bone tissue leading to low bone mass and bone fragility, especially in the older age. The condition affects both sexes; however women are more prone to it, especially post-menopause when bone loss is accelerated due to reduced estrogen, which helps protect the bones.
Statistics:
The global and China osteoporosis drugs market is estimated to account for US$ 17.1 Bn in terms of value by the end of 2027.
Global and China Osteoporosis Drugs Market: Drivers
Increasing prevalence of osteoporosis is expected to propel growth of the global and China osteoporosis drugs market over the forecast period. For instance, according to the study, ‘The Prevalence of Osteoporosis in China, a Nationwide, Multicenter DXA Survey’, published in October 2019, in The Journal of Bone and Mineral Research, the age-standardized prevalence of osteoporosis at the spine or hip was 6.46% and 29.13% for men and women aged 50 years and older, respectively. A total of 10.9 million men and 49.3 million women in China were estimated to have osteoporosis.
Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the United Nations, Department of Economic and Social Affairs, Population Division, the geriatric population in China is expected to reach 246,986 thousands in 2030 from 164,487 thousands in 2019.
Statistics:
North America held dominant position in the global and China osteoporosis drugs market in 2019, accounting for 38.5% share in terms of value, followed by Europe and Asia Pacific, respectively.
Figure 1: Global and China Osteoporosis Drugs Market Share (%) Value, By Region, 2019
Global and China Osteoporosis Drugs Market: Restraints
Adverse effects of osteoporosis drugs are expected to hinder growth of the market. For instance, consumption of alendronate may lead to stomach pain, acid reflux, constipation, diarrhea, upset stomach, nausea, or muscle and joint pain.
Moreover, low awareness and diagnosis of osteoporosis, especially in emerging economies is also expected to limit the market growth.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2019: | US$ 12.7 Bn |
| Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 3.8% | 2027 Value Projection: | US$ 17.1 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Merck & Co., Eli Lilly, Procter & Gamble, Enzo Biochem, Inc., Sanofi-Aventis, Novartis, Wyeth, Roche, GlaxoSmithKline, UCB, Amgen, BeiGene Co., Ltd., Bone Biologics, Teijin Pharma Limited, JHL Biotech Inc., Keros Therapeutics, and Taro Pharmaceuticals Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Global and China Osteoporosis Drugs Market: Opportunities
R&D in novel therapeutics is expected to offer lucrative growth opportunities for players in the global and China osteoporosis drugs market. For instance, in June 2020, researchers from School of Medicine CHA University, South Korea, reported that Tauroursodeoxycholic acid, the U.S. FDA-approved hydrophilic bile acid for the treatment of chronic cholestatic liver disease, may provide a favorable effect on bones and could be used for the prevention and treatment of osteoporosis.
Moreover, increasing number of smokers is also expected to aid in growth of the market. For instance, according to the World Health Organization, 1.337 billion people smoked tobacco worldwide in 2018.
Statistics:
The global and China osteoporosis drugs market was valued at US$ 12.7 Bn in 2019 and is forecast to reach a value of US$ 17.1 Bn by 2027 at a CAGR of 3.8% between 2020 and 2027.
Figure 2: Global and China Osteoporosis Drugs Market Value (US$ Bn), 2016 – 2027
Market Trends/Key Takeaways
Major organizations are focused on reducing the burden of osteoporosis. For instance, in June 2020, The International Osteoporosis Foundation partnered with Amgen and UCB, a global biopharmaceutical company, in collaboration with the University of Oxford, to support its Capture the Fracture program, which aims to reduce hip and vertebral fractures by 25% by 2025.
Approval and launch of AI-based products to predict osteoporosis is expected to aid in growth of the market. For instance, in May 2020, Zebra Medical Vision received FDA 510(k) clearance for its Vertebral Compression Fractures product, which automatically identifies findings suggestive of compression fractures, which enables clinicians to place patients that are at risk of osteoporosis in treatment pathways.
Global and China Osteoporosis Drugs Market: Competitive Landscape
Major players operating in the global and China osteoporosis drugs market include, Merck & Co., Eli Lilly, Procter & Gamble, Enzo Biochem, Inc., Sanofi-Aventis, Novartis, Wyeth, Roche, GlaxoSmithKline, UCB, Amgen, BeiGene Co., Ltd., Bone Biologics, Teijin Pharma Limited, JHL Biotech Inc., Keros Therapeutics, and Taro Pharmaceuticals Inc.
Global and China Osteoporosis Drugs Market: Key Developments
Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in May 2020, Teijin Pharma Limited, a partner of Radius Health, Inc., submitted a New Drug Application for abaloparatide-SC in Japan for the treatment of osteoporosis in patients who are at high risk for fractures.
Similarly, in April 2019, Amgen and UCB received the U.S. Food and Drug Administration approval for EVENITY (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
Osteoporosis is characterized by reduction in the density and quality of bones that often result in broken bones in the wrist, hip, and spine. Various factors responsible for osteoporosis include, genetic factors, low intake of calcium, magnesium, and vitamin D, eating disorders such as anorexia, inactivity and immobility, and excessive alcohol intake. Increasing approvals and launches of novel osteoporosis drugs along with increasing prevalence of osteoporasis is expected to significantly drive the osteoporosis treatment market growth over forecast period.
Key features of the study:
Detailed Segmentation:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients